AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37691729
Drug: Golimumab (GLM)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab (GLM) 100 mg (for nonresponders)
Trial: 37691796
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy (active control)
Trial: 37691850
Drug: Menthol solution
RxNorm normalized name: Menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menthol solution 0.01%
Trial: 37691850
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - noncaloric berry-flavored solution
Trial: 37691885
Drug: Paclitaxel liposome,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel liposome, cisplatin and 5-fluorouracil (TPF)-based induction chemotherapy followed by de-escalated radiotherapy of 60 Gy with concurrent cisplatin
Trial: 37691885
Drug: Paclitaxel liposome,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel liposome, cisplatin and 5-fluorouracil (TPF)-based induction chemotherapy followed by standard-dose radiotherapy of 70 Gy with concurrent cisplatin (for those with stable or progressive disease)
Trial: 37692126
Drug: Tezepelumab 210
RxNorm normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab 210 mg every 4 weeks for 52 weeks
Trial: 37692969
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of nabiximols (up to 113.4 mg THC/105 mg CBD)
Trial: 37693269
Drug: Retreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retreatment with first-line anti-HCV drugs for 24 weeks with ribavirin
Trial: 37693269
Drug: Overall retreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall retreatment with first-line anti-HCV drugs
Trial: 37693433
Drug: Pre-treatment functional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment functional connectivity of the seed with the cerebellum, insula, middle occipital gyrus, postcentral gyrus, and precuneus/superior parietal lobule.
Trial: 37693433
Drug: Pre-treatment functional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment functional connectivity with the putamen.
Trial: 37693433
Drug: Pre- to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre- to post-treatment changes in functional connectivity.
Trial: 37693433
Drug: Pre-treatment functional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment functional connectivity between regions involved in attentional salience, self-generated thoughts, and external attention.
Trial: 37693586
Drug: Pre-treatment histidine
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-treatment histidine concentration
Trial: 37693586
Drug: Pre-treatment concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment concentrations of glutamate
Trial: 37693586
Drug: Pre-treatment concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment concentrations of phenylalanine
Trial: 37693586
Drug: Pre-treatment concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment concentrations of tyrosine
Trial: 37693586
Drug: Pre-treatment concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment concentrations of valine
Trial: 37693768
Drug: Low-frequency rTMS
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency rTMS (30 min) followed by occupational therapy (30 min) for 10 consecutive workdays
Trial: 37693768
Drug: Sham rTMS
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham rTMS (30 min) followed by occupational therapy (30 min) for 10 consecutive workdays
Trial: 37694347
Drug: T-DXd 5.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-DXd 5.4 mg/kg
Trial: 37694347
Drug: T-DXd 6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-DXd 6.4 mg/kg
Trial: 37694449
Drug: Garetosmab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garetosmab (10 mg/kg, intravenous, every 4 weeks)
Trial: 37694449
Drug: Placebo (intravenous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intravenous, every 4 weeks)
Trial: 37696393
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept treatment
Trial: 37696588
Drug: Bimekizumab (BKZ)
RxNorm normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Bimekizumab (BKZ) 160 mg every 4 weeks
Trial: 37696588
Drug: Adalimumab (ADA)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab (ADA) 40 mg every 2 weeks
Trial: 37696588
Drug: Bimekizumab (BKZ)
RxNorm normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Bimekizumab (BKZ) 160 mg every 4 weeks (after switch from PBO at Week 16)
Trial: 38279364
Drug: Otilimab 90
RxNorm normalized name: Otilimab
DrugBank: Otilimab (DB06303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otilimab 90 mg
Trial: 37699654
Drug: Otilimab 150
RxNorm normalized name: Otilimab
DrugBank: Otilimab (DB06303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otilimab 150 mg
Trial: 37696629
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg melatonin administered rectally via an enema daily for 28 days
Trial: 37696629
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered rectally via an enema daily for 28 days
Trial: 37696935
Drug: lefitolimod (TLR9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lefitolimod (TLR9 agonist)/placebo
Trial: 37696935
Drug: placebo/broadly neutralizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo/broadly neutralizing anti-HIV-1 antibodies (bNAbs)
Trial: 37697331
Drug: Secondary factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary factors (symptoms, activity level, activities of daily living, sport)
Trial: 37697491
Drug: Oral rinse
RxNorm normalized name: Oral Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rinse activated matrix metalloproteinase-8 (aMMP-8) point-of-care test (POCT)
Trial: 37697666
Drug: Ultrasound-guided hydrodilatation
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided hydrodilatation with hyaluronic acid (20 mL in total) + physical therapy
Trial: 37697666
Drug: Ultrasound-guided hydrodilatation
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided hydrodilatation with hyaluronic acid + physical therapy
Trial: 37697813
Drug: Heparin bridging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin bridging strategy used during edoxaban interruption (178 procedures)
Trial: 37698478
Drug: High-dose Erythropoietin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Erythropoietin
Trial: 37698662
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of triamcinolone acetonide (TA) (40 mg) and VISCOAT (sodium chondroitin sulfate 20 mg and sodium hyaluronate 15 mg)
Trial: 37698662
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (TA) (40 mg) in the posterior subtenon space
Trial: 37698662
Drug: Suprachoroidal triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suprachoroidal triamcinolone (4 mg/100µl)
Trial: 37698660
Drug: Modified Monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Monthly Regimen (mMR), total dose-5.5 g, with intake of oral GCs after completion of intravenous infusions.
Trial: 37698660
Drug: Weekly Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly Regimen (WR), total dose-4.5 g.
Trial: 37698660
Drug: Modified Monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Monthly Regimen (mMR)
Trial: 37698660
Drug: Weekly Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly Regimen (WR)
Trial: 37698745
Drug: Mobile health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile health exercise intervention (daily steps and resistance training data entered into an app)
Trial: 37698836
Drug: 120-mg galcanezumab
RxNorm normalized name: galcanezumab-gnlm 120 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120-mg galcanezumab
Trial: 37698836
Drug: 240-mg galcanezumab
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 240-mg galcanezumab
Trial: 37699050
Drug: E-liquids with
RxNorm normalized name: Aquasol E Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-liquids with 20 mg/mL total nicotine concentration
Trial: 37699050
Drug: E-liquids with
RxNorm normalized name: Aquasol E Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-liquids with 50 mg/mL total nicotine concentration
Trial: 37699064
Drug: 120 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 μg RSVPreF3-AS01E (third dose)
Trial: 37699064
Drug: Previous 2
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous 2 doses of RSVPreF3-AS01E
Trial: 37699161
Drug: START (Startle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: START (Startle Adjuvant Rehabilitation Therapy) with 105-dB white noise GO cues during one third of trials
Trial: 37699161
Drug: START (Startle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: START (Startle Adjuvant Rehabilitation Therapy)
Trial: 37699162
Drug: Alpelisib (PIK3CA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpelisib (PIK3CA inhibitor)
Trial: 37699162
Drug: Poziotinib (EGFR/HER2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poziotinib (EGFR/HER2 inhibitor)
Trial: 37699162
Drug: Nintedanib (FGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib (FGFR inhibitor)
Trial: 37699162
Drug: Abemaciclib (CDK4/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib (CDK4/6 inhibitor)
Trial: 37699162
Drug: Durvalumab ±
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab ± Tremelimumab (anti-PD-L1/CTLA-4 inhibitor)
Trial: 37699237
Drug: Managing chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Managing chemotherapy symptoms (e.g., medication, home remedies)
Trial: 37699237
Drug: Anticipating and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticipating and mitigating symptoms (e.g., management of symptoms at home, anticipatory guidance)
Trial: 37699237
Drug: Knowing when
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Knowing when to seek care (e.g., unexpected and unusual symptoms)
Trial: 37699601
Drug: Scalp-sparing volumetric-modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalp-sparing volumetric-modulated arc therapy (SSV)
Trial: 37699634
Drug: Anti-PD-1 treatment
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 treatment (Tislelizumab) starting at Day 8 of radiation (concurrent plan)
Trial: 37699634
Drug: Anti-PD-1 treatment
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 treatment (Tislelizumab) starting 2 weeks after completion of radiation (sequential plan)
Trial: 37699634
Drug: Long-course radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-course radiotherapy plus concurrent capecitabine (control arm)
Trial: 37699634
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment (all arms)
Trial: 37699709
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous KPL-404 dose 0.03, 0.3, 1, 3, or 10 mg/kg
Trial: 37699709
Drug: Single subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous KPL-404 dose 1 or 5 mg/kg
Trial: 37700239
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 inhibitor
Trial: 37700249
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous ascorbic acid (50 mg/kg every 6 h for 96 h)
Trial: 37700288
Drug: EWS plus
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Dews Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EWS plus medication therapy management (EWS + MTM)
Trial: 37700334
Drug: Daily smartphone-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily smartphone-based monitoring and treatment including clinical feedback
Trial: 37700334
Drug: Daily smartphone-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily smartphone-based monitoring without clinical feedback
Trial: 37700334
Drug: Daily smartphone-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily smartphone-based mood monitoring only
Trial: 37701986
Drug: Pembrolizumab-based combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab-based combination therapy
Trial: 37702047
Drug: Dietary nitrate
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary nitrate supplementation (400 mg nitrate in 70 mL beetroot juice)
Trial: 37702427
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics (OA) combined with mechanical bowel preparation (MBP)
Trial: 37702453
Drug: Topical pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical pilocarpine HCl 1.25% (Pilo)
Trial: 37702588
Drug: Temsirolimus 25
RxNorm normalized name: temsirolimus 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus 25 mg i.v. on days 1, 8, 15, and 22 and bevacizumab 10 mg/kg i.v. on days 1 and 15 of a 4-week cycle
Trial: 37702588
Drug: Temsirolimus and
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus and bevacizumab combination therapy
Trial: 37702920
Drug: Sotrovimab 500
RxNorm normalized name: sotrovimab 500 MG in 8 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotrovimab 500 mg (intravenous infusion on Day 1)
Trial: 37703006
Drug: Evinacumab, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evinacumab, 15 mg/kg, intravenously Q4W
Trial: 37703037
Drug: Dialectical Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavior Therapy (DBT) for 1 year (36 sessions)
Trial: 37703083
Drug: Elexacaftor/Tezacaftor/Ivacaftor treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elexacaftor/Tezacaftor/Ivacaftor treatment
Trial: 37703248
Drug: Mindfulness-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based intervention (MBI) delivered by ecological momentary intervention (EMI) via a smartphone app, including daily practice prompts, mindfulness exercises, virtual counseling, and daily psychological status logs.
Trial: 37703397
Drug: Open lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open lidocaine administration
Trial: 37703397
Drug: Open capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open capsaicin administration
Trial: 37703397
Drug: Hidden lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hidden lidocaine administration
Trial: 37703397
Drug: Hidden capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hidden capsaicin administration
Trial: 37703908
Drug: Ciclosporin (2-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin (2-3 mg/kg before transplantation and 3 mg/kg twice per day from postoperative day 1)
Trial: 37703908
Drug: Tacrolimus (0.05-0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (0.05-0.1 mg/kg before transplantation and 0.1-0.2 mg/kg from postoperative day 1)
Trial: 37704438
Drug: Unilateral anterior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral anterior quadratus lumborum block (30 mL of ropivacaine 0.375%)
Trial: 37704499
Drug: Second booster
RxNorm normalized name: 60 Second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second booster doses of monovalent COVID-19 vaccines (AZD1222, Ad26.COV2.S, CoronaVac, BNT162b2)
Trial: 37704499
Drug: First booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First booster doses of monovalent COVID-19 vaccines
Trial: 37704753
Drug: CDK4/6 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK4/6 inhibitors (palbociclib) in combination with aromatase inhibitors (AI) or fulvestrant (FUL)
Trial: 37704942
Drug: Micronutrient supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient supplementation (two oral capsules daily for three months)
Trial: 37704984
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) for chronic pain (10 weeks)
Trial: 37705074
Drug: Mobile-based coaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile-based coaching intervention (WeChat mini-program) with 180 educational videos for 6 months and standard treatment
Trial: 37705369
Drug: Hybrid approach
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid approach using drug-eluting stent (DES) and drug-coated balloon (DCB)
Trial: 37705424
Drug: Alglucosidase alfa
RxNorm normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Alglucosidase alfa 20 mg/kg body weight, single intravenous dose
Trial: 37705972
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies (including rituximab and abatacept)
Trial: 37706025
Drug: Wharton Jelly-derived
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wharton Jelly-derived Mesenchymal Stromal Cells (WJ-MSCs) - 1 intravenous infusion of 1 × 10
Trial: 37706457
Drug: Auricular Point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular Point Acupressure (APA) treatment administered by nurses for 3 days, with patients instructed to stimulate the points 3 times per day for 3 minutes each time.
Trial: 37706580
Drug: ATG-targeted dosing
RxNorm normalized name: ATG-101
DrugBank: ATG-101 (DB17162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG-targeted dosing strategy
Trial: 37706580
Drug: Conventional fixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fixed ATG dose (historical control)
Trial: 37707791
Drug: Durvalumab (anti-PD-L1)
RxNorm normalized name: Protease-activated anti-pd-l1 antibody prodrug cx-072
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab (anti-PD-L1) monotherapy
Trial: 37707820
Drug: Individualized stereotactic
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized stereotactic ablative radiotherapy (SABR) with doses ranging from 25 Gy in 1 fraction for peripheral tumors (0-10 cm3) to 60 Gy in 8 fractions for central tumors (>30 cm3).
Trial: 37707942
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm received daily walk step reminders to walk at least 5000 steps per day
Trial: 37707944
Drug: Internet-based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based Cognitive Behavioral Therapy (iCBT) with Virtual Reality Exposure Therapy (VRET) - 14-week program including 9 web-based modules and 5 individual counseling sessions (2 VRET sessions)
Trial: 37707956
Drug: Inhibitors and
RxNorm normalized name: ACE inhibitors and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitors and mimics of miRNAs
Trial: 37708435
Drug: Mobile health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile health application designed to increase AUD treatment engagement
Trial: 37708528
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol (17-g dose by mouth on postoperative day 1)
Trial: 37708528
Drug: Docusate sodium
RxNorm normalized name: Docusate Sodium
DrugBank: Docusate (DB11089)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docusate sodium (100 mg starting the day of surgery and continued twice daily at home)